



Final Appraisal Recommendation

Advice No: 1312 – June 2012

Rilpivirine (Edurant®) 25 mg film-coated tablet

Submission by Janssen-Cilag Ltd

Recommendation of the All Wales Medicines Strategy Group

Rilpivirine (Edurant®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients with a viral load $\leq 100,000$ HIV-1 RNA copies/ml, in combination with other antiretroviral medicinal products.

Additional note:

- AWMSG is of the opinion that rilpivirine (Edurant®) is appropriate for specialist only prescribing within NHS Wales for the above indication

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 557), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation-1312: Rilpivirine (Edurant®) 25 mg film-coated tablet. June 2012.